Skip to content
OpenCapital
Get started

Vor Biopharma VOR Q1 2025 earnings

Reported May 14, 2025 · Before market open

Diluted EPS-$0.26Miss by $0.01
EPS estimate-$0.25

Next report

Aug 11, 2026 (In 4 weeks)
EPS estimate-$0.69

Financials

Q1 2025

Income statement

See full
Operating income-$33.3M-3.0%
Net income-$32.5M-5.5%
EPS (diluted)-$5.21-1,058%

Balance sheet

See full
Cash & equivalents$50.0M+11.3%
Total debt$30.8M-11.4%
Total equity$66.1M-46.3%
Total assets$109.3M-34.6%

Cash flow

See full
Operating cash flow-$31.1M-2.0%
CapEx$231.0K+103%
Free cash flow-$31.3M-2.3%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$89.58M-44.3%
Enterprise value$70.32M-53.3%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio3.9×-4.6×

Versus estimates

Diluted EPS

Q1 2026-$0.73Beat by $0.02Q4 2025$82.04Beat by $83.18Q3 2025-$3.33Miss by $0.27Q2 2025-$43.60Miss by $32.20
Q1 2025-$0.26Miss by $0.01
Q4 2024-$0.44Miss by $0.10

Ask the moment Vor Biopharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Vor Biopharma report Q1 2025 earnings?
Vor Biopharma (VOR) reported Q1 2025 earnings on May 14, 2025 before market open.
What were Vor Biopharma's Q1 2025 revenue and EPS?
Vor Biopharma reported diluted EPS of $-0.26 for Q1 2025.
Did Vor Biopharma beat estimates in Q1 2025?
EPS missed the consensus estimate of $-0.25 by $0.01.
How did Vor Biopharma's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 42.2% from $-0.45.
Where can I find Vor Biopharma's Q1 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-071349) directly on SEC EDGAR. The filing index links above go to sec.gov.